Patent expiry and costs for anti-cancer medicines for clinical use

Brian Godman; Claudia Wild; Alan Haycox

doi:10.5639/gabij.2017.0603.021

Patent expiry and costs for anti-cancer medicines for clinical use

Brian Godman^*, Claudia Wild, Alan Haycox

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

24 Citations (Scopus)

Abstract

Venkatesan S et al. have researched patent rights and pricing for (non-)tyrosine kinase inhibitors. It is not clear why the patent rights are so long and why prices of (non-)tyrosine kinase inhibitors can be high. These issues are discussed.

Original language	English
Pages (from-to)	105-106
Number of pages	2
Journal	GaBI Journal
Volume	6
Issue number	3
DOIs	https://doi.org/10.5639/gabij.2017.0603.021
Publication status	Published - 2017
Externally published	Yes

Keywords

Cancer medicines
Generics
Health gain
Prices
Tyrosine kinase inhibitors (TKI)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5639/gabij.2017.0603.021

Cite this

@article{f248666e988f49ceba3e133868ee3977,

title = "Patent expiry and costs for anti-cancer medicines for clinical use",

abstract = "Venkatesan S et al. have researched patent rights and pricing for (non-)tyrosine kinase inhibitors. It is not clear why the patent rights are so long and why prices of (non-)tyrosine kinase inhibitors can be high. These issues are discussed.",

keywords = "Cancer medicines, Generics, Health gain, Prices, Tyrosine kinase inhibitors (TKI)",

author = "Brian Godman and Claudia Wild and Alan Haycox",

note = "Publisher Copyright: {\textcopyright} 2017 Pro Pharma Communications International.",

year = "2017",

doi = "10.5639/gabij.2017.0603.021",

language = "English",

volume = "6",

pages = "105--106",

journal = "GaBI Journal",

issn = "2033-6403",

publisher = "Pro Pharma Communications International",

number = "3",

}

TY - JOUR

T1 - Patent expiry and costs for anti-cancer medicines for clinical use

AU - Godman, Brian

AU - Wild, Claudia

AU - Haycox, Alan

PY - 2017

Y1 - 2017

N2 - Venkatesan S et al. have researched patent rights and pricing for (non-)tyrosine kinase inhibitors. It is not clear why the patent rights are so long and why prices of (non-)tyrosine kinase inhibitors can be high. These issues are discussed.

AB - Venkatesan S et al. have researched patent rights and pricing for (non-)tyrosine kinase inhibitors. It is not clear why the patent rights are so long and why prices of (non-)tyrosine kinase inhibitors can be high. These issues are discussed.

KW - Cancer medicines

KW - Generics

KW - Health gain

KW - Prices

KW - Tyrosine kinase inhibitors (TKI)

UR - https://www.scopus.com/pages/publications/85033362837

U2 - 10.5639/gabij.2017.0603.021

DO - 10.5639/gabij.2017.0603.021

M3 - Comment/debate

AN - SCOPUS:85033362837

SN - 2033-6403

VL - 6

SP - 105

EP - 106

JO - GaBI Journal

JF - GaBI Journal

IS - 3

ER -

Patent expiry and costs for anti-cancer medicines for clinical use

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this